Presatovir

Presatovir (also known as GS-5806) is an experimental antiviral drug developed by Gilead Sciences for the treatment of respiratory syncytial virus (RSV) infections. It is a first-in-class oral RSV fusion inhibitor that has shown promise in early-stage clinical trials.

Mechanism of Action

Presatovir works by inhibiting the fusion of the RSV virus with the host cell membrane, preventing the virus from entering the cell and thereby stopping the infection from spreading. This mechanism of action is unique among antiviral drugs, which typically work by inhibiting viral replication after the virus has already entered the cell.

Clinical Trials

Presatovir has undergone Phase 2 clinical trials for the treatment of RSV in lung transplant patients. In these trials, the drug was well-tolerated and showed a significant reduction in the viral load of RSV in the patients' respiratory tracts.

Potential Applications

While Presatovir is currently being developed for the treatment of RSV, its unique mechanism of action could potentially make it effective against other viral infections as well. Further research is needed to explore these potential applications.

See Also

• Antiviral drug
• Respiratory syncytial virus
• Gilead Sciences